STUDYING THE POSSIBLE LINK OF LIFESTYLE HABITS AND CYTOKINE BIOMARKERS AMONG THE PROSTATE CANCER PATIENTS

ABBAS ABDULHASAN JEBUR; RAKESH M RAWAL; RUSHIKESH JOSHI; SUDHAKAR MALLA

doi:10.22159/ajpcr.2025v18i8.54946

Authors

ABBAS ABDULHASAN JEBUR Department of Biochemistry and Forensic Science, Gujarat University, Ahmedabad, Gujarat, India
RAKESH M RAWAL Department of Biochemistry and Forensic Science, Gujarat University, Ahmedabad, Gujarat, India
RUSHIKESH JOSHI Department of Biochemistry and Forensic Science, Gujarat University, Ahmedabad, Gujarat, India
SUDHAKAR MALLA Insearch Biotech Laboratory, Bengaluru, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i8.54946

Keywords:

Prostate cancer, C-reactive protein, Erythrocyte sedimentation rate, Smoking, Enzyme-linked immunosorbent assay, Cytokines, Interleukins, Interleukin-2, Interleukin-10, Interleukin-17A

Abstract

Objectives: Men over 50 are the main victims of prostate cancer (PCa), a non-cutaneous malignancy. It kills more than 3,000 individuals worldwide and affects more than 1.6 million people. We intended to examine the potential relationship between PCa incidence and age trends as well as PCa and cytokine levels in the current investigation.

Methods: The study was conducted between January 2019 and March 2020 and was a prospective longitudinal observational study. The study included 70 patients (n=70) with PCa who were receiving standard chemotherapy at the Gujarat Medical College Urology Service (control=20 healthy individuals). We intended to investigate the prevalence of cancer as well as lifestyle choices such as smoking and drinking.

Results: We found from the data that the subjects in the age group from 61 to 65 were more susceptible to the disease (p<0.05). There is no direct correlation between smoking habits and the incidence of cancer. We found the cytokines in the study also to be elevated significantly when compared to the controls (p<0.05). Interleukin (IL-20 and IL-4 levels were elevated to 25.67±2.132 and 45.63±3.4512, respectively, when compared to control. Il-6 and IL-10 levels were elevated to 65.43±1.654 and 12.341±2.1218, respectively, when compared to control. On the other hand, Il-17A levels were elevated to 45.33±3.121 from 16.11±1.1132 (control).

Conclusion: When combined, our findings offer the whole set of pro-inflammatory markers required for a thorough evaluation and diagnosis of PCa patients. The cytokines IL-2, 4, 6, 8, 10, and 17A may serve as indications of the progression of PCa as well as biomarkers for its pathogenesis.

Downloads

Download data is not yet available.

References

1. Chen J, Zhang D, Yan W, Yang D, Shen B. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. Biomed Res Int. 2013;2013:901578. doi: 10.1155/2013/901578, PMID 23957008

2. Termini D, Den Hartogh DJ, Jaglanian A, Tsiani E. Curcumin against prostate cancer: Current evidence. Biomolecules. 2020;10(11):1536. doi: 10.3390/biom10111536, PMID 33182828

3. Cittadini A, Isidori AM, Salzano A. Testosterone therapy and cardiovascular diseases. Cardiovasc Res. 2022;118(9):2039-57. doi: 10.1093/cvr/cvab241, PMID 34293112

4. Takayama KI. Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling. Biomolecules. 2019;9(4):131. doi: 10.3390/biom9040131, PMID 30939845

5. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: Report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063-75. doi: 10.1200/GO.20.00122, PMID 32673076

6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660, PMID 33538338

7. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. doi: 10.1101/cshperspect.a030361, PMID 29311132

8. Bhardwaj P, Au CM, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R, et al. Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019;189:161-70. doi: 10.1016/j.jsbmb.2019.03.002, PMID 30851382

9. Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, Pack S, Clot G, Nadeu F, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682-93. doi: 10.3324/haematol.2020.271957, PMID 33951889

10. Ugge H, Downer MK, Carlsson J, Bowden M, Davidsson S, Mucci LA, et al. Circulating inflammation markers and prostate cancer. Prostate. 2019;79(11):1338-46. doi: 10.1002/pros.23842, PMID 31212389

11. Toriola AT, Laukkanen JA, Kurl S, Nyyssönen K, Ronkainen K, Kauhanen J. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer. 2013;133(12):2961-7. doi: 10.1002/ ijc.28313, PMID 23754532

12. Garrido MM, Ribeiro RM, Krüger K, Pinheiro LC, Guimarães JT, Holdenrieder S. Are proinflammatory cytokines relevant for the diagnosis of prostate cancer? Anticancer Res. 2021;41(6):3067-73. doi: 10.21873/anticanres.15090, PMID 34083299

13. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009;124(11):2683-9. doi: 10.1002/ijc.24241, PMID 19189403

14. Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, et al. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1966-72. doi: 10.1158/1055-9965.EPI-07-0302, PMID 17932343

15. Roumeguère T, Legrand F, Rassy EE, Kaitouni MI, Albisinni S, Rousseau A, et al. A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer. Future Sci OA. 2018;4(2):FSO266. doi: 10.4155/fsoa-2017-0084, PMID 29379640

16. Xu S, Hu Y, Zhang L, Yue S, Zhang L, Liang C. Association of cytokine gene polymorphisms with prostate cancer risk from a study in central China. Contrast Media Mol Imaging. 2022;2022:1259009. doi: 10.1155/2022/1259009, PMID 36034203

17. Li BH, Yan SY, Luo LS, Zeng XT, Wang YB, Wang XH. Ten interleukins and risk of prostate cancer. Front Oncol. 2023;13(13):1108633. doi: 10.3389/fonc.2023.1108633, PMID 36733309, PMCID PMC9887118

18. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev. 2001;23(1):3-13. doi: 10.1093/ oxfordjournals.epirev.a000792, PMID 11588851

19. Eapen RS, Herlemann A, Washington SL, 3rd, Cooperberg MR. Impact of the United States preventive services task force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol. 2017;27(3):205-9. doi: 10.1097/MOU.0000000000000383, PMID 28221220

20. Sailo SL, Sailo LP, Stonewann VC. Clinicopathological profile of prostate cancer patients: A 10 years retrospective study from a tertiary care centre, North East India. J Clin Diagn Res. 2022;16:PC7-10. doi: 10.7860/JCDR/2022/57485.17161

21. Hariharan K, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol. 2016;32(2):103-8. doi: 10.4103/0970-1591.174774, PMID 27127351

22. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012(45):152-6. doi: 10.1093/ jncimonographs/lgs035, PMID 23271766, PMCID PMC3540881

23. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63- 89. doi: 10.14740/wjon1191, PMID 31068988, PMCID PMC6497009

24. Yang X, Chen H, Zhang S, Chen X, Sheng Y, Pang J. Association of cigarette smoking habits with the risk of prostate cancer: A systematic review and meta-analysis. BMC Public Health. 2023;23(1):1150. doi: 10.1186/s12889-023-16085-w, PMID 37316851

25. De Nunzio C, Tema G, Trucchi A, Cicione A, Sica A, Lombardo R, et al. Smoking reduces PSA accuracy for detection of prostate cancer: Results from an Italian cross-sectional study. Minerva Urol Nefrol. 2019;71(6):583-9. doi: 10.23736/S0393-2249.19.03360-5, PMID 31144489

26. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol. 2004;31(6):726-33. doi: 10.1053/j.seminoncol.2004.09.013, PMID 15599850

27. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: An overview for clinicians. CA Cancer J Clin. 2014;64(4):272-90. doi: 10.3322/caac.21231, PMID 24817674

28. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D’Andrea D, et al. Association of smoking status with recurrence, metastasis, and mortality among patients with localized prostate cancer undergoing prostatectomy or radiotherapy: A systematic review and meta-analysis. JAMA Oncol. 2018;4(7):953-61. doi: 10.1001/jamaoncol.2018.1071, PMID 29800115

29. Johansson JE, Sigurdsson T, Holmberg L, Bergström R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. Cancer. 1992;70(6):1556-63. doi: 10.1002/1097-0142(19920915)70:6<1556:aid-cncr2820700619>3.0.co;2-i, PMID 1516006

30. Eklund CM, Tammela TL, Schleutker J, Hurme M. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Cancer. 2009;100(12):1846-51. doi: 10.1038/sj.bjc.6605081, PMID 19436291

31. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171(2 Pt 2):S36-40. doi: 10.1097/01. ju.0000108131.43160.77, PMID 14713751

32. Watts EL, Perez-Cornago A, Kothari J, Allen NE, Travis RC, Key TJ. Hematologic markers and prostate cancer risk: A prospective analysis in UK Biobank. Cancer Epidemiol Biomarkers Prev. 2020;29(8):1615-26. doi: 10.1158/1055-9965.EPI-19-1525, PMID 32457180

33. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: A systematic review and meta-analysis. Cancer Epidemiol. 2014;38(4):329-38. doi: 10.1016/j. canep.2014.06.002, PMID 24986642

34. Ghoshal K, Bhattacharyya M. Overview of platelet physiology: Its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorldJournal. 2014;2014:781857. doi: 10.1155/2014/781857, PMID 24729754

35. Doat S, Marous M, Rebillard X, Trétarre B, Lamy PJ, Soares P, et al. Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study. Int J Cancer. 2018;143(7):1644-51. doi: 10.1002/ ijc.31565, PMID 29696626

36. Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. doi: 10.1080/2162402X.2016.1163462, PMID 27471638

37. Chen R, Liu L, Chen H, Xing C, Zhang T, Pang Y, et al. Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer. Cancer Immunol Immunother. 2024;73(8):139. doi: 10.1007/s00262-024-03723-4, PMID 38833027

38. Mao C, Ding Y, Xu N. A double-edged sword role of cytokines in prostate cancer immunotherapy. Front Oncol. 2021 Nov 16;11:688489. doi: 10.3389/fonc.2021.688489, PMID 34868907

39. Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, et al. Interleukin-4 in patients with prostate cancer. Anticancer Res. 2005;25(6C):4595-8. PMID 16334148

40. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000;164(3 Pt 1):722-5. doi: 10.1097/00005392-200009010-00024, PMID 10953133

41. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int. 2014 Jun;113(6):986-92. doi: 10.1111/bju.12452, PMID 24053309

42. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001 Dec;159(6):2159-65. doi: 10.1016/S0002-9440(10)63067-2, PMID 11733366

43. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000 Feb 15;42(3):239-42. doi: 10.1002/(sici)1097- 0045(20000215)42:3<239:aid-pros10>3.0.co;2-g, PMID 10639195

44. Thomas CE, Bauer DC, Yuan JM, Cauley JA. Circulating IL-10 is associated with reduced risk of prostate cancer in a prospective cohort of elderly men: The MrOS study. Cancer Causes Control. 2023 Jan;34(1):59-68. doi: 10.1007/s10552-022-01639-x, PMID 36239865

45. Ouyang W, O’Garra A. IL-10 family cytokines IL-10 and IL-22: From basic science to clinical translation. Immunity. 2019;50(4):871-91. doi: 10.1016/j.immuni.2019.03.020, PMID 30995504

46. Chen KY, Chien WC, Liao JM, Tsai CW, Chang WS, Su CH, et al. Contribution of interleukin-10 genotype to triple negative breast cancer risk. Anticancer Res. 2021;41(5):2451-7. doi: 10.21873/ anticanres.15020, PMID 33952470

47. Al-janaby MS, Al-ani MQ, Rasheed MN. Relationship between some immunological factors and type 2 diabetes mellitus in Iraqi patients. Asian J Pharm Clin Res. 2018 Jun;11(6):489-92. doi: 10.22159/ ajpcr.2018.v11i6.25881

48. Elbaz FK, Aly HF, Khalil WK, Ali GH, Booles HF. Haematococcus pluvialis extract promoting the recovery of memory impairment in Alzheimer’s rats: Anti-inflammatory and antiapoptotic effects. Asian J Pharm Clin Res. 2016 Dec;9(9):171-7. doi: 10.22159/ajpcr.2016. v9s3.14715

49. Singh A, Jaiswal V, Bisht S. Advances in cocrystals of anticancer agents: Formulation strategies and therapeutic implications. Int J Pharm Pharm Sci. 2024 Jun;16(6):27-32. doi: 10.22159/ijpps.2024v16i6.51044

50. Kiełb P, Kaczorowski M, Kowalczyk K, Piotrowska A, Nowak Ł, Krajewski W, et al. Role of IL-17A and IL-17RA in prostate cancer with lymph nodes metastasis: Expression patterns and clinical significance. Cancers (Basel). 2023 Sep 15;15(18):4578. doi: 10.3390/ cancers15184578, PMID 37760548

51. Na G, Ge S, Ying Z, Moustafa AA, Dongxia G, Zongbing Y. Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression. Front Oncol. 2019;9:546.